BlackRock Inc. disclosed a new investment in ADMA Biologics on August 27, 2026. The asset manager acquired 38,355,684 shares of the biotechnology firm during the second quarter. This position is valued at approximately $321 million.
The purchase grants BlackRock a 16.55% ownership stake in the company. Algert Global LLC also increased its holdings in the firm by 118.3% during the same period.
Institutional interest of this scale typically signals confidence in a company’s future prospects. Reports did not specify an immediate market reaction following the SEC filing.